



HAL
open science

Addressing mental health problems among persons without stable housing in the context of the COVID-19 pandemic: study protocol for a randomised trial.

RESPOND – France

Maria Melchior, Natasha Figueiredo, Aurélia Roversi, Alexandre Dubanchet, Eric Bui, Julian Vadell-Martínez, Corrado Barbui, Marianna Purgato, José Luis Ayuso-Mateos, Roberto Mediavilla, et al.

► To cite this version:

Maria Melchior, Natasha Figueiredo, Aurélia Roversi, Alexandre Dubanchet, Eric Bui, et al.. Addressing mental health problems among persons without stable housing in the context of the COVID-19 pandemic: study protocol for a randomised trial. RESPOND – France. BMC Public Health, 2023, 23 (1), pp.2275. 10.1186/s12889-023-17238-7. hal-04381856

HAL Id: hal-04381856

<https://hal.science/hal-04381856>

Submitted on 9 Jan 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Addressing mental health problems among persons without stable housing in the context of the**
2 **COVID-19 pandemic: study protocol for a randomised trial. RESPOND – France**

3 Maria Melchior (corresponding author)¹, Natasha Figueiredo¹, Aurélie Roversi¹, Alexandre
4 Dubanchet², Eric Bui², Julian Vadell-Martínez¹, Corrado Barbui³, Marianna Purgato³, José Luis Ayuso-
5 Mateos^{4,5,6}, Roberto Mediavilla^{4,5,6}, David McDaid⁷, A-La Park⁷, Papoula Petri-Romão^{8,9}, Raffael
6 Kalisch^{8,9}, Pablo Nicaise¹⁰, Vincent Lorant¹⁰, Marit Sijbrandij¹¹, Anke B. Witteveen¹¹, Richard Bryant¹²,
7 Mireia Felez¹³, James Underhill¹⁴, Giulia Pollice¹, Andrea Tortelli^{1,15}

8
9 1 : Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP),
10 (Equipe de Recherche en Epidémiologie Sociale), F75012, Paris, France

11
12 2: CHU Caen, & Normandie Univ, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of
13 Neurological Disorders", NeuroPresage Team, Cyceron, 14000 Caen, France.

14
15 3. Department of Neuroscience, Biomedicine, and Movement Sciences, Section of Psychiatry, WHO
16 Collaborating Centre for Research and Training in Mental Health and Service Evaluation, University of
17 Verona, Verona, Italy

18
19 4. Department of Psychiatry, Universidad Autónoma de Madrid (UAM), Madrid, Spain

20
21 5. Instituto de Investigación Sanitaria del Hospital Universitario La Princesa, Madrid, Spain

22
23 6. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos
24 III, Madrid, Spain

25
26 7. Care Policy and Evaluation Centre, Department of Health Policy, London School of Economics and
27 Political Science, London, UK

28
29 8. Leibniz Institute for Resilience Research (LIR), Mainz, Germany

30
31 9. Neuroimaging Center (NIC), Focus Program Translational Neuroscience (FTN), Johannes Gutenberg
32 University Medical Center, Mainz, Germany

33
34 10. Institute of Health and Society (IRSS), Université Catholique de Louvain, Brussels, Belgium

35
36 11. Clinical, Neuro and Developmental Psychology, WHO Collaborating Centre for Research and
37 Dissemination of Psychological Interventions, Amsterdam Public Health Institute, VU University,
38 Amsterdam, the Netherlands.

39
40 12. School of Psychology, University of New South Wales, Sydney, Australia

41
42 13. Institut de recerca Sant Joan de Déu, Dr. Antoni Pujadas, 4208830 Sant Boi de Llobregat
43 (Barcelona), Spain

44 14 : Brighton, UK

45
46 15 : GHU Paris, Psychiatrie & Neurosciences – Pôle Psychiatrie Précarité, Paris, France

47
48 Corresponding author: Maria Melchior (maria.melchior@inserm.fr)

49

1 **Abstract**

2 Background: The COVID-19 pandemic has had an impact on population-wide mental health and well-
3 being. Although people experiencing socioeconomic disadvantage may be especially vulnerable, they
4 experience barriers in accessing mental health care. To overcome these barriers, the World Health
5 Organization (WHO) designed two scalable psychosocial interventions, namely the web-based Doing
6 What Matters in Times of Stress (DWM) and the face-to-face Problem Management Plus (PM+), to
7 help people manage stressful situations. Our study aims to test the effectiveness of a stepped-care
8 program using DWM and PM+ among individuals experiencing unstable housing in France – a
9 majority of whom are migrant or have sought asylum.

10 Methods: This is a randomised controlled trial to evaluate the effectiveness and cost effectiveness of
11 a stepped-care program using DWM and PM+ among persons with psychological distress and
12 experiencing unstable housing, in comparison to enhanced care as usual (eCAU). Participants (N=210)
13 will be randomised to two parallel groups: eCAU or eCAU plus the stepped-care program. The main
14 study outcomes are symptoms of depression and anxiety measured using the Patient Health
15 Questionnaire Anxiety and Depression Scale (PHQ-ADS).

16 Discussion: This randomised controlled trial will contribute to a better understanding of effective
17 community-based scalable strategies that can help address the mental health needs of persons
18 experiencing socioeconomic disadvantage, whose needs are high yet who frequently have limited
19 access to mental health care services.

20 Trial registration: this randomised trial has been registered at ClinicalTrials.gov under the number
21 NCT05033210.

22 **Keywords:** Randomized Controlled Trial; Psychological Distress; COVID-19; Housing Instability;
23 Migrant; Doing What Matters in Times of Stress; Problem Management Plus; Economic Evaluation;
24 France

1 Word count: Abstract: 258 words; Main Text: 3610; Figure: 1; Table: 2; Supplementary Table 1 &
2 document

1 **Background**

2 The COVID-19 pandemic has contributed to a worldwide increase in the prevalence of psychological
3 distress and symptoms of anxiety and depression, (1) although this has recently been a matter of
4 some debate, in part due to heterogeneity in findings across different stages of the sanitary crisis.(2)
5 While in the general population the increase in mental health problems was observed in 2020 and
6 appears to have decreased afterwards, this may not be the case in marginalized groups. In particular,
7 research has highlighted a high prevalence of mental health problems among individuals
8 experiencing socioeconomic disadvantage compared to the general population.(3, 4) Mental health
9 care systems are thus facing difficulties in addressing this growing demand , which may result in
10 delays or unmet needs, increasing existing social inequalities in mental health and health care
11 access.(5)

12 In France in recent years, and more particularly in the Paris area, there has been an increase in the
13 number of people who are homeless, sleeping rough or experience unstable housing conditions,
14 among whom a large proportion are recent migrants and asylum seekers due in part to changes in
15 migratory patterns and asylum regulations which contribute to newcomers' social vulnerability (6). In
16 addition to social disadvantage, this group often experiences violence, discrimination, and isolation,
17 as well as cultural and language barriers before, during and after migration,(7) and should have
18 priority in terms of prevention of health conditions and treatment. However, this group experiences
19 widely documented unmet needs in terms of mental health care. The COVID-19 pandemic has
20 resulted in increased difficulties in accessing mental health care at large and in marginalized
21 populations, calling for the evaluation of new scalable psychosocial interventions.

22 To make mental health care accessible, it is necessary to adapt it. For that purpose, the World Health
23 Organization (WHO) has developed a number of scalable psychological interventions based on
24 Acceptance and Commitment Therapy (ACT) including Doing What Matters in Times of Stress
25 (DWM)(8) and Problem Management Plus (PM+)(9). DWM is a self-help stress management guide
26 that includes pre-recorded audio exercises and illustrations, introducing participants to five different

1 strategies to relieve stress (e.g. mindfulness exercises) and has been shown to reduce psychological
2 distress across multiple trials(10, 11). To be widely accessible, DWM has been adapted for individual
3 use as a mobile-supported website with distance support by a trained person spread over the course
4 of 5 weeks. Self-Help + (SH+), is an intervention based on the DMW manual. The PM+ intervention is
5 based on principles of Cognitive Behavioural Therapy (CBT) and Problem-Solving Therapy and can be
6 delivered by non-specialists in situations where mental health care is not accessible. PM+ has four
7 core features: it is brief (five sessions); delivered by non-specialist helpers; transdiagnostic (it
8 addresses depression, anxiety, post-traumatic stress disorder, psychological distress); it was
9 originally designed for individuals living in communities with limited mental health care resources but
10 is easily adaptable to different populations, cultures and languages. Organised in 5 sessions, PM+ can
11 be delivered individually or in groups of adults experiencing distress to help them develop problem
12 management strategies. Both individual and group formats of PM+ have been shown to reduce
13 anxiety and depression(12, 13).

14 These interventions do not replace specialised mental health care for people with severe psychiatric
15 disorders, but contribute to reducing psychological distress and decrease later risk of mental
16 disorders among persons with mild to moderate manifestations.

17 The main aim of the present randomised controlled trial (RCT) is to evaluate the effectiveness of the
18 stepped-care program combining DWM and PM+ to reduce symptoms of depression and anxiety
19 amongst adults experiencing unstable housing in comparison to enhanced care-as-usual (eCAU). The
20 secondary objectives are to evaluate: (a) the effect of the intervention on participants' quality of life
21 and resilience; (b) the moderation of the effect of the intervention by participants' socio-
22 demographic characteristics, living conditions, and experiences of trauma (i.e. individuals who have
23 lower levels of education, less stable housing situation, and higher levels of trauma are expected to
24 benefit less from the psychosocial program being tested); (c) the resource impacts and cost-
25 effectiveness of DWM and PM+ interventions. In France, a large proportion of individuals

1 experiencing unstable housing conditions and sheltered in collective accommodation facilities are
2 migrants (6), therefore the DWM and PM+ protocols were professionally translated and back
3 translated by study helpers who are native speakers and trained translators to languages most
4 frequently spoken by recent asylum seekers and migrants to France (Dari and Pashto); we also used
5 the existing Arabic translation provided by the WHO (14). The study being conducted under the
6 supervision of a psychiatrist (AT), the validity of the tools used to screen for psychological distress
7 can be validated after the trial. PM+ was previously used in studies conducted across different parts
8 of the world (for instance in Pakistan and among Syrian refugees to Jordan)(12, 15). Prior to the
9 implementation of this randomised controlled trial, we conducted a pilot study in 2019-2020 to test
10 the feasibility of recruiting participants for this intervention among people who do not speak French
11 and reside in temporary accommodation. The pilot study allowed us to make a number of
12 adjustments to study recruitment procedures (for instance the selection of participating
13 accommodation centres) and research questionnaires, as well as estimate attrition. The present RCT
14 is part of the Horizon 2020 cross-national RESPOND project (Australia, Belgium, France, Germany,
15 Italy, Netherlands, Spain, Sweden and the United Kingdom) aiming to test effective ways of
16 addressing population mental health needs following the COVID-19 pandemic(16, 17). This protocol
17 was not peer-reviewed as part of the funding process.

18 **Methods: Participants, intervention and outcomes**

19 Study setting

20 This study is set in the Paris and Caen regions in France, among people who experience unstable
21 housing conditions (that is individuals who are homeless and are sheltered in temporary
22 accommodation, by other people, or have no regular shelter) recruited via temporary
23 accommodation centres as well as ambulatory care for people who experience social disadvantage
24 and/or are migrant. The Paris region traditionally attracts new migrants because it concentrates
25 economic resources. As a result, it is a region where many infrastructures serve migrants – particularly

1 those experiencing social disadvantage, making recruitment easier. As for Caen, it has also become
2 an area concentrating migrants, due to its proximity to the UK. Moreover, one of the study's
3 collaborators (Dr. Bui) is based in Caen. We acknowledge that the selection of study locations may be
4 a limitation of the protocol.

6 Eligibility criteria

7 Individuals will be able to participate in the trial if they are 18 years of age or older, have elevated
8 levels of psychological distress as assessed with the Kessler-10 scale (K10 score ≥ 15.9)(18), speak one
9 of the study languages (Arabic, Dari, French, Pashto), find themselves without stable housing and are
10 willing to participate.

11 Exclusion criteria include having an acute medical or psychiatric condition requiring urgent medical
12 attention (e.g. hospitalization) as ascertained by the consultant psychiatrist involved in the trial (Dr.
13 AT), a high risk of suicide, moderate/severe cognitive impairment (e.g. severe intellectual disability or
14 dementia), being under legal protection (guardianship, curatorship, safeguard of justice), a change in
15 the level of psychotropic treatment in the two months preceding the trial (as ascertained in the
16 baseline study questionnaire at T1), and refusal to participate.

17 Interventions

18 This is a randomized controlled study, comparing a stepped-care intervention to enhanced Care as
19 Usual (all participants will receive Psychological First Aid, PFA, prior to treatment allocation). All study
20 assessments and interventions are described in Figure1. Participants randomly allocated to the
21 intervention arm through the electronic platform used to collect study data will first receive the
22 DWM intervention for 5 weeks (weeks 2 to 6). At the end of the DWM intervention, participants will
23 complete the first follow-up questionnaire (T2 - week 7), which includes the K10 scale to evaluate
24 whether they still experience high levels of psychological distress (K10 score ≥ 15.9). If so, they will

1 receive the PM+ intervention for the next 5 weeks (weeks 8 to 12) and then answer the second
2 follow up questionnaire (T3 - week 13). Otherwise, they will skip the PM+ intervention and only
3 complete a follow-up questionnaire at week 13. Two months later, participants will complete the last
4 follow-up questionnaire (T4 - week 21).

5 Participants allocated to the control group will complete the study questionnaires (T1, T2, T3 and T4)
6 at the same time points as the intervention group and will not receive the DWM/PM+ stepped-care
7 program. The control group consists of enhanced Care as Usual, as participants receive Psychological
8 First Aid (PFA) in addition to standard treatment.

9 1. Psychological First Aid (PFA) is a support strategy that involves humane, supportive and practical
10 help for individuals experiencing a serious collective crisis (19) delivered to all study participants in
11 both trial arms. PFA consists of a conversation (approximately 30-45 minutes) which can be provided
12 remotely (e.g. videoconferencing or telephone). This conversation has various themes; non-intruding
13 practical care and support, description of mental health needs and concerns, information about ways
14 of addressing individuals' basic needs, provision of comfort and help staying calm, help connecting to
15 services and social support, as well as protection of individuals from further harm(20).

16 2. Doing What Matters in times of stress (DWM) is a self-help stress management guide based on the
17 principles of Acceptance and Commitment Therapy (ACT). DWM includes five sections, each of which
18 focuses on a specific skill (Grounding; Unhooking; Acting on your values; Being kind; Making room).
19 In this study, DWM will be delivered online, via a web-based program designed to be used on a
20 smartphone with the assistance of a helper. Helper support will be flexible, and on average occur
21 once a week for approximately 15-20 minutes. Every week over the course of five weeks, a new
22 module will be unlocked.

23 3. Problem Management + (PM+) is a brief, psychological intervention based on cognitive
24 behavioural therapy (CBT) techniques that are empirically supported, formally recommended and
25 developed by the WHO. The manual involves the following empirically supported elements: problem


1 solving, stress management, behavioural activation, and accessing social support. In 60-minute
2 sessions, participants talk to trained non-professional helpers. PM+ sessions will be conducted face-
3 to-face by a helper, also over a five-week period at a rate of one session per week.

4 The cultural acceptability of DMW and PM+ among potential study participants and social workers
5 attending to their needs was verified in qualitative research prior to study inception.

6 For both DWM and PM+, manuals can be accessed online(8, 9).

7

8 **Figure 1. Framework of the RESPOND trial – France**



1

2

3 Study outcomes

4 Table 1 shows all the measures collected across study questionnaires (from T1 to T4).

1 The primary study outcome is the Patient Health Questionnaire-Anxiety and Depression Score (PHQ-
2 ADS), a sum of scores on the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety
3 Disorder -7 (GAD-7), two scales evaluating respectively symptoms of depression and of generalised
4 anxiety disorder(21, 22). The PHQ-9 includes 9 items and the GAD-7 comprises 7 items, the combined
5 score ranging from 0 to 48. Elevated scores indicate a higher level of symptoms of depression and
6 anxiety. Two validation studies of the PHQ-ADS among patients with chronic pain and cancers have
7 been summarized and published(22). This score has strong internal reliability (Cronbach's alpha of
8 0.8 and 0.9), strong convergent validity, sufficient uni-dimensionality and is sensitive to change.

9 As secondary study outcomes, we will use the PHQ-9 alone(23), the GAD-7 alone(24), as well as other
10 measures of participants' mental health: the Patient Checklist-5 (PCL-5) assessing symptoms of Post-
11 Traumatic Stress Disorder(25), Psychotic Symptoms assessed using the MINI questionnaire(26) and
12 quality of life assessed using the EQ-5D-5L(27). Additionally, we will assess outcome-based resilience,
13 which is operationalised as the individual deviation from the sample-based normative stressor
14 reactivity, that is a difference between individual-level observed and sample-based predicted values
15 of psychological distress considering a certain number of stressors. Resilience will be calculated
16 with a measure of stressor exposure which has been adapted from the Mainz Inventory of
17 Microstressors (MIMIS) and the PHQ-9 and GAD-7(28).

18 Additionally, baseline and follow-up study questionnaires will ascertain participants'
19 sociodemographic characteristics (sex, age, nationality, educational level, income, etc.), as well as
20 COVID-19-related stressors (that is 11 items relative to worries regarding COVID-19 infection and
21 possible stigma due to contamination, as well as loss of income, employment or basic life resources
22 due to COVID-19 and possible administrative complications related to the sanitary crisis and its
23 aftermath). Furthermore, participants are asked to report on their appraisal style using the Perceived
24 Positive Appraisal Style Scale, content-focused version (PASSc)(28). Moreover participants' stress

1 levels will be assessed using the Brief Trauma Questionnaire (BTQ)(29). Finally, cost-effectiveness of
2 the intervention will also be examined.

3 Participant timeline

4 Each participant will be in the study for 21 weeks.

5 Sample size

6 Overall, 210 participants will be included. Based on previous studies of PM+(30, 31), we aim to detect
7 a small to medium effect size corresponding to a Cohen's $d = 0.4$ in the intervention group at 2
8 months, as measured with the PHQ-ADS and as compared to the control group. A calculation of
9 statistical power for a repeated measures study design (mixed regression model), given incomplete
10 participation in each of the planned assessments, suggests a minimum sample size of $n = 73$ per group
11 (power=0.80, $\alpha = 0.05$, bilateral, $\rho = 0.9$). Considering an attrition rate of 30%, estimated based
12 on a prior pilot study and past evaluations of PM+, we calculated a total number of 210 participants
13 needed (105 in each group). If needed, missing data on study covariates will be handled using
14 standard multiple imputation techniques.

15 Recruitment

16 Participants are recruited directly in temporary accommodation centres as well as ambulatory care
17 for people experiencing social disadvantage and/or who are migrant, by trained helpers who are in
18 contact with each site's coordinator and regularly visit to list potential participants and contact them.
19 Recruitment and allocation started in March 2022 and is should be completed by the end of October,
20 2023. The first post-allocation took place in July 2022 and the last one will take place in February
21 2024, study close-out should occur in February 2024. To enhance retention and reduce study drop-
22 out, participants are compensated 3×20 euros (at T1, T3 and T4). We also cover their travel expenses
23 if they are interviewed on research premises rather than at the accommodation centre where they
24 live.

1 Adverse events

2 Any undesirable experience occurring during the study, whether or not considered related to the trial
3 procedure or the stepped-care DWM/PM+ program, will be considered an Adverse Event. All adverse
4 events reported spontaneously by study participants or observed by the investigators will be
5 recorded and reported to the promoting agency (ANRS-MIE).

6 **Methods : Assignment of intervention**

7 To evaluate the effectiveness and cost effectiveness of the DMW/PM+ stepped-care program, we will
8 conduct an RCT comparing the DMW/PM+ stepped-care programme to enhanced care-as-usual
9 (n=105 each), delivered after all participants receive psychological first aid (PFA). After verification of
10 inclusion criteria, participants will be randomly allocated to the intervention or eCAU based on a 1:1
11 basis, via the Castor Electronic Data Capture web-based software, also used to collect study data.

12 This electronic tool applies a variable block randomization method, randomly permuting blocks of
13 unequal size. The site investigators will be blind to the block size and will not have access to the
14 randomization list.

15 Blinding of participants and data collectors to the intervention will not be possible due to the nature
16 of the intervention being evaluated.

17 **Methods : Data collection, management, analysis**

18 A total of 210 participants will be recruited in two locations: Paris and Caen (Normandy, North
19 Western France). In Paris, recruitment activities will be conducted via mental health care ambulatory
20 services dedicated to migrants who experience social disadvantage (Precarity Unit of the GHU Paris,
21 the largest psychiatric hospital in Paris), and accommodation centres for homeless people and
22 asylum seekers. In Caen, participants will be recruited from accommodation centres for the
23 homeless.

1 Potential participants will be informed about the study and given one week to decide whether they
2 want to enrol. Participants who accept to enrol in the study and sign the informed consent form will
3 complete the study screening questionnaire, which includes the K10 scale screening for psychological
4 distress, as well as measures of sociodemographic and health characteristics. Participants who meet
5 all inclusion criteria will complete the first study questionnaire and will be randomly allocated to one
6 of the two study groups: intervention (PFA, DWM and PM+ and CAU) or eCAU (PFA and CAU) (T1 -
7 week 1).

8 Five helpers will be recruited to implement PFA, DWM and PM+ among study participants. All helpers
9 will be specially trained by a Master trainer and supervised weekly by a clinical psychologist
10 throughout the study.

11 Prior to the recruitment of the first study participant, qualitative research activities were
12 implemented to better understand the perceptions and expectations of eligible individuals. Initial
13 qualitative interviews were conducted with 22 potential study participants as well as 26 professionals
14 working in temporary accommodation centres, who are key in identifying and referring potential
15 study participants. These qualitative interviews made it possible to adapt the research tools (for
16 example the wording used in DMW and research questionnaires), as well as assess the acceptability
17 of the proposed research protocol. At the end of the project, qualitative interviews with study
18 participants as well as social workers and other support staff, will collect participants' feedback and
19 help gain information on ways of disseminating the program broadly.

20

Table 1: Measures assessed in the RESPOND Randomised Trial France.

Measures	Screening (T1)	Follow-up at 7 weeks (T2)	Follow-up at 13 weeks (T3)	Follow-up at 21 weeks (T4)
K10 (psychological distress) ¹⁶	x	x		
Suicidal risk	x			
Suicidal screening step by step ³⁶	x	x	x	x
PHQ-9 (symptoms of depression) ²¹⁻²³	x	x	x	x
GAD-7 (symptoms of generalized anxiety disorder) ²⁴⁻²⁷	x	x	x	x
PCL-5 (symptoms of post-traumatic stress disorder) ²⁸⁻³⁰	x	x	x	x
PSYCHLOPS (Psychological Outcome Profiles) ³⁷	x	x	x	x

Stress reactivity scores	x	x	x	x
PASSc (STRENGTHS (Syrian REfuGees MeNTal Health Care Systems) ³⁸	x	x	x	x
EQ-5D-5L (quality of life) ³²	x	x	x	x
MINI (psychotic symptoms) ³¹	x	x	x	x
CSRI (Client Service Receipt Inventory) ³⁹	x	x	x	x
Sociodemographics	x	x	x	x
BTQ (Brief trauma test) ⁴⁰	x		x	x
Impact of COVID-19 on daily life activities	x	x	x	x
Satisfaction with DWM ¹²		x		

Satisfaction with PM+ ¹³			x	
-------------------------------------	--	--	---	--

Data collection methods

All study questionnaires (from T0 to T3) will be administered by a member of the research team or by a trained helper (**Table 1**). Face-to-face data collection will be prioritised but video or telephone meetings will be allowed if needed. Questionnaire administration and randomisation will be implemented using CASTOR EDC, an electronic CRF (eCRF). Table 2 describes the SPIRIT diagram for the schedule of enrolment, intervention and assessment.

Table 2: SPIRIT diagram for the schedule of enrolment, intervention and assessment in the RESPOND Randomised Trial France.

	Study period						
	Enrolment	Allocation	DMW	Post allocation			Close-out
	T0	T1		T2 (Week 7)	PM+	T3 (Week 13)	T4 (Week 21)
Enrolment	x						
<i>Information about the study</i>	x						
<i>Eligibility screen</i>		x					
<i>Informed consent</i>		x					
Allocation		x					
Interventions		x					
<i>Intervention group</i>		x					
<i>Control group</i>		x					
Assessments		x		x		x	x

Data management

Quantitative data obtained from study questionnaires being collected on an eCRF will be automatically stored electronically. Each participant will be identified with a unique numerical identifier, all personal data used to contact participants being stored separately and securely. In compliance with French regulations, all data will be stored for two years after the end of the trial. In

case of adverse events, information will be systematically collected, forwarded to the promoting agency and if necessary participation will be stopped. The trial will be audited after completion.

Statistical methods

The data will be analysed using: (a) an intention-to-treat (ITT) analysis, which will include all participants recruited for the study (n=210); (b) an analysis among participants who complete the program (per protocol - PP). The statistical analyses will be masked, *i.e.* the trial statistician will be blind to the group allocation until the analysis is complete. In addition, the trial statistician will not be involved in participant eligibility determination, intervention administration, outcome measurement, or data entry.

To estimate the effect of the intervention, a linear mixed model will be used. The intervention will be included as a fixed effect, the subject as the random effect, the baseline score of the primary outcome as a covariate. A covariate-adjusted linear mixed model of the primary endpoint will also be implemented adding covariates pre-specified at study baseline (gender, age, education, COVID-19-related events, and symptom severity, as well as pre-existing levels of depression and anxiety). The primary analysis will assess treatment effect on the average PHQ-ADS score at each time-point in the ITT population. The main conclusion of the trial will be drawn from this ITT analysis (*i.e.*, the effect on PHQ-ADS score at the 2-month follow-up). In addition to the main analysis, secondary analyses will also be implemented. First, participants' levels of psychological distress (PM+), symptoms of posttraumatic stress disorder (PCL-5), and quality of life (EQ-5D-5L) will be evaluated at one-month post DWM (T2), as well as one week (T3) and two months post PM+ (T4). Second, changes in the number of cases of depression will be calculated in the PP sample using a logistic regression model. Third, the role of perceived positive appraisal style as measured by PASSc in relation to the first and secondary outcomes will be explored. Fourth, outcome-based resilience will be examined using mental health symptoms against stressor exposure. All statistical analyses will be implemented using Rstudio.

Economic analysis

The primary outcome for the economic analysis will be the incremental costs per QALY gained between the intervention and comparator groups. The total costs of delivering interventions will be estimated and combined with data on changes in health service utilisation and time out of usual activity (from T1 to T4) obtained using a bespoke version of the Client Service Receipt Inventory (CSRI)(32), an instrument widely used for the collection of self-report service utilisation. Unit costs will be defined depending on the type of resource used. In addition to using the CSRI, we will collate information on the resources and costs of implementing the intervention, including initial and ongoing training/supervision. EQ-5D-3L questionnaire responses from participants will be transformed into a preference-based index utility score using published French population tariffs(33) and QALYs will be calculated using the area under the curve approach. The economic analysis will be conducted from both the health care system and societal perspectives. Between-group comparisons of mean costs will be undertaken using appropriate statistical tests depending on the type and distribution of data. Univariate sensitivity analyses and non-parametric bootstrapping will be used to account for uncertainty in trial parameters and cost effectiveness planes will be generated. Cost-effectiveness acceptability curves will be constructed to indicate the likelihood that the intervention will be cost-effective at different levels of willingness to pay. The economic analysis will be conducted using STATA and SPSS.

Ethics and dissemination

This research has obtained the approval of the Ethics Committee “*Île de France III*” on July 7 2021 (Comité de Protection des Personnes, 3858-I) and of the National body regulating data protection on February 2nd 2022 (Commission Nationale Informatique et Libertés, MLD /MFI/AR221796). The RESPOND Project - France respects the ethical principles stated in the reviewed version of the Helsinki Declaration of October 2013. The RESPOND trial is overseen by a Project Advisory Board,

which includes independent experts and relevant stakeholders. Protocol amendments will be notified to the Comité de Protection des Personnes and authorization will be sought.

Conclusion

Our study will test the effectiveness and cost-effectiveness of a stepped-care program including DWM and PM+, hypothesised to provide support to persons experiencing psychological distress and having difficulty accessing healthcare. Evidence suggests that stepped-care models are modestly effective(32), although there is a high heterogeneity of such models (number of steps, duration of steps, rules about stepping up) and their effects, implying the need for further research.

Interestingly, there is also evidence that health care providers benefit from a switch from a matched care to a stepped-care approach(34). Stepped-care interventions are both innovative and affordable since they can be administered face-to-face or remotely by non-professional helpers who receive special training. They could be particularly well-suited for people who experience social disadvantage, such as persons with an unstable housing situation and migrants, and face multiple barriers to access healthcare.

Overall, this study will contribute to identifying the impact of stepped-care programs on reducing psychological distress among marginalized populations who experience high levels of psychological distress yet have difficulty accessing mental health care. Results will contribute to providing effective community-based health care implementation strategies to scale-up the delivery and uptake of evidence-based mental health interventions in different contexts to address the specific needs. They will be disseminated to scientists, decisionmakers as well as study participants through dedicated publications and the Internet.

Declarations

Ethics approval and consent to participate

This research has obtained the approval of the Ethics Committee “*Île de France III*” on July 7th, 2021 (Comité de Protection des Personnes, 3858-I), of the National body regulating data protection on February 2nd, 2022 (Commission Nationale Informatique et Libertés, MLD /MFI/AR221796). The RESPOND Project - France respects the ethical principles stated in the reviewed version of the Helsinki Declaration of October 2013. All participants sign an informed consent. The study has performed in accordance with the Declaration of Helsinki.

Consent for publication

Our manuscript does not contain individual data, therefore this category does not apply.

Availability of data and materials

Data collected in the RESPOND Project - France are available from the authors (maria.melchior@inserm.fr) upon reasonable request and with permission of INSERM | ANRS-MIE.

Competing interests

The authors declare that they have no competing interests.

Funding

This study is embedded in the larger, EU Horizon 2020 H2020-SC1-PHE-CORONAVIRUS-2020-2 funded RESPOND (Improving the Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns resulting from the COVID-19 Pandemic) project (Grant Agreement 101016127). The RESPOND project is composed of a consortium of eight countries: the Netherlands, France, Spain, Italy, Belgium, United Kingdom, Sweden, Australia. The funder has no influence in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication.

Authors' contributions

MM and AT conceived the study, coordinated its design, and drafted and wrote the manuscript. NF, AR, JV and EB participated in conceptualizing the study as well as writing the manuscript. All authors read and were involved in critical appraisal and revision of the manuscript and approved the final manuscript.

Acknowledgements

The authors wish to acknowledge WHO staff who have contributed to the development of Doing What Matters and Problem Management+, as well as ANRS-MIE staff who were involved in helping finalize the study protocol and obtain all necessary ethical and regulatory authorizations.

References

1. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet*. 2021;398(10312):1700-12.
2. Witteveen AB, Young SY, Cuijpers P, Ayuso-Mateos JL, Barbui C, Bertolini F, et al. COVID-19 and common mental health symptoms in the early phase of the pandemic: An umbrella review of the evidence. *PLoS Medicine*. 2023;20(4):e1004206.
3. Wang Y, Kala MP, Jafar TH. Factors associated with psychological distress during the coronavirus disease 2019 (COVID-19) pandemic on the predominantly general population: A systematic review and meta-analysis. *PLoS One*. 2020;15(12):e0244630.
4. Camara C, Surkan PJ, Van Der Waerden J, Tortelli A, Downes N, Vuillermoz C, et al. COVID-19-related mental health difficulties among marginalised populations: A literature review. *Global Mental Health*. 2023;10:e2.
5. Stevens AJ, Ray AM, Thirunavukarasu A, Johnson E, Jones L, Miller A, et al. The experiences of socially vulnerable groups in England during the COVID-19 pandemic: A rapid health needs assessment. *Public Health Practice*. 2021;2:100192.
6. Roze M, Vandentorren S, van der Waerden J, Melchior M. Factors associated with depression among homeless mothers. Results of the ENFAMS survey. *Journal of Affective Disorders*. 2018;229:314-21.
7. Champion J, Bhugra D, Bailey S, Marmot M. Inequality and mental disorders: opportunities for action. *Lancet*. 2013;382(9888):183-4.
8. Organization WH. Doing what matters in times of stress. 2020.
9. Organization WH. Problem Management Plus (PM+): Individual psychological health for adults impaired by distress in communities exposed to adversity. 2016.
10. Acarturk C, Uygun E, Ilkkursun Z, Carswell K, Tedeschi F, Batu M, et al. Effectiveness of a WHO self-help psychological intervention for preventing mental disorders among Syrian refugees in Turkey: a randomized controlled trial. *World Psychiatry*. 2022;21(1):88-95.
11. Tol WA, Leku MR, Lakin DP, Carswell K, Augustinavicius J, Adaku A, et al. Guided self-help to reduce psychological distress in South Sudanese female refugees in Uganda: a cluster randomised trial. *Lancet Global Health*. 2020;8(2):e254-e63.

12. Bryant RA, Bawaneh A, Awwad M, Al-Hayek H, Giardinelli L, Whitney C, et al. Effectiveness of a brief group behavioral intervention for common mental disorders in Syrian refugees in Jordan: A randomized controlled trial. *PLoS Medicine*. 2022;19(3):e1003949.
13. Rahman A, Khan MN, Hamdani SU, Chiumento A, Akhtar P, Nazir H, et al. Effectiveness of a brief group psychological intervention for women in a post-conflict setting in Pakistan: a single-blind, cluster, randomised controlled trial. *Lancet*. 2019;393(10182):1733-44.
14. Guisao AJ, C Quere, M Laporte, A Riou, F La santé des migrants primo-arrivants: résultats des bilans infirmiers réalisés d'octobre 2015 à mars 2016 dans des centres franciliens hébergeant des migrants évacués des campements parisiens. *Bulletin Épidémiologique Hebdomadaire*. 2017;19-20:382-8.
15. Hamdani SU, Ahmed Z, Sijbrandij M, Nazir H, Masood A, Akhtar P, et al. Problem Management Plus (PM+) in the management of common mental disorders in a specialized mental healthcare facility in Pakistan; study protocol for a randomized controlled trial. *International journal of mental health systems*. 2017;11:40.
16. Mediavilla R, McGreevy KR, Felez-Nobrega M, Monistrol-Mula A, Bravo-Ortiz MF, Bayón C, et al. Effectiveness of a stepped-care programme of internet-based psychological interventions for healthcare workers with psychological distress: Study protocol for the RESPOND healthcare workers randomised controlled trial. *Digital health*. 2022;8:20552076221129084.
17. Purgato M, Turrini G, Tedeschi F, Serra R, Tarsitani L, Compri B, et al. Effectiveness of a stepped-care programme of WHO psychological interventions in migrant populations resettled in Italy: Study protocol for the RESPOND randomized controlled trial. *Frontiers in public health*. 2023;11:1100546.
18. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. *Psychological Medicine*. 2002;32(6):959-76.
19. Hobfoll SE, Watson P, Bell CC, Bryant RA, Brymer MJ, Friedman MJ, et al. Five essential elements of immediate and mid-term mass trauma intervention: empirical evidence. *Psychiatry*. 2007;70(4):283-315; discussion 6-69.
20. Organization WH. Psychological first aid. 2013.
21. Kroenke K, Wu J, Yu Z, Bair MJ, Kean J, Stump T, et al. Patient Health Questionnaire Anxiety and Depression Scale: Initial validation in three clinical trials. *Psychosomatic Medicine*. 2016;78(6):716-27.
22. Kroenke K, Baye F, Lourens SG. Comparative validity and responsiveness of PHQ-ADS and other composite anxiety-depression measures. *Journal of Affective Disorders*. 2019;246:437-43.
23. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *Journal of General Internal Medicine*. 2001;16(9):606-13.
24. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Archives of Internal Medicine*. 2006;166(10):1092-7.
25. Ashbaugh AR, Houle-Johnson S, Herbert C, El-Hage W, Brunet A. Psychometric validation of the English and French versions of the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5). *PLoS One*. 2016;11(10):e0161645.
26. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *JClinPsychiatry*. 1998;59 Suppl;22-33.
27. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Quality of Life Research*. 2011;20(10):1727-36.
28. Kalisch R, Köber G, Binder H, Ahrens KF, Basten U, Chmitorz A, et al. The Frequent Stressor and Mental Health Monitoring-Paradigm: A Proposal for the operationalization and measurement of resilience and the identification of resilience processes in longitudinal observational studies. *Frontiers in psychology*. 2021;12:710493.

29. Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, et al. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. *Psychological Assessment*. 2018;30(3):383-95.
30. Rahman A, Hamdani SU, Awan NR, Bryant RA, Dawson KS, Khan MF, et al. Effect of a multicomponent behavioral intervention in adults impaired by psychological distress in a conflict-affected area of Pakistan: a Randomized Clinical Trial. *Jama*. 2016;316(24):2609-17.
31. Bryant RA, Schafer A, Dawson KS, Anjuri D, Mulili C, Ndogoni L, et al. Effectiveness of a brief behavioural intervention on psychological distress among women with a history of gender-based violence in urban Kenya: A randomised clinical trial. *PLoS Medicine*. 2017;14(8):e1002371.
32. Beecham JK, M. Costing psychiatric interventions. *Measurement of Mental Health Needs* 2001;2.
33. Andrade LF, Ludwig K, Goni JMR, Oppe M, de Pouvourville G. A French Value Set for the EQ-5D-5L. *Pharmacoeconomics*. 2020;38(4):413-25.
34. Boyd L, Baker E, Reilly J. Impact of a progressive stepped care approach in an improving access to psychological therapies service: An observational study. *PLoS One*. 2019;14(4):e0214715.